NGM Biopharmaceuticals $125 million follow-on offering
We advised the joint book-running managers on the public equity offering
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Gamida Cell $75 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $75 million SEC-registered follow-on offering of 9,343,750 ordinary shares of Gamida Cell Ltd, which…
Solid Biosciences $90 million common stock PIPE offering
Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Solid Biosciences Inc. of $90 million of common stock.
Solid Biosciences Inc…
Atara Biotherapeutics $175 million common stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $175 million SEC-registered common stock and pre-funded warrants…
Seer $336 million IPO and concurrent private placement
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 10,592,106 shares of Class A common stock of Seer, Inc. at $19.00 per…
Oak Street Health $297.9 million secondary offering
Davis Polk advised the joint book-running managers in connection with the $297.9 million secondary offering of 6,477,293 shares of common stock of Oak Street Health, Inc. by certain…
BeiGene $340 million secondary offering
Davis Polk advised the underwriter in connection with the $340 million SEC-registered offering of 1,511,546 American depositary shares of BeiGene, Ltd. by certain existing ADS holders. The…
Notre Dame Intermédica R$3.8 billion equity offering
Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Bain Capital, the controlling shareholder of Notre Dame Intermédica, of 54,000,000…
RAPT Therapeutics $100 million at-the-market offering
Davis Polk advised the sales agents on the SEC-registered at-the-market offering by RAPT Therapeutics, Inc. of its common stock for up to an aggregate amount of $100 million.
RAPT…
Revance Therapeutics $125 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Revance Therapeutics, Inc. of its common stock for up to an aggregate amount of $125 million.
Based…